Literature DB >> 23850200

A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core.

Guillaume Duvey1, Benjamin Perry, Emmanuel Le Poul, Sonia Poli, Beatrice Bonnet, Nathalie Lambeng, Delphine Charvin, Tansy Donovan-Rodrigues, Hasnaà Haddouk, Stefania Gagliardi, Jean-Philippe Rocher.   

Abstract

A series of potent non-acetylinic negative allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 NAMs) was developed starting from HTS screening hit 1. Potency was improved via iterative SAR, and physicochemical properties were optimized to deliver orally bioavailable compounds acceptable for in vivo testing. A lead molecule from the series demonstrated dose-dependent activity in the second phase of the rat formalin test from 30 mg/kg, and a preliminary PK/PD relationship was established.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allosteric; Glutamate; Metabotropic; Pain; mGlu5

Mesh:

Substances:

Year:  2013        PMID: 23850200     DOI: 10.1016/j.bmcl.2013.06.044

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson's Disease.

Authors:  Wen Yuan Luo; Su Qian Xing; Ping Zhu; Chen Guang Zhang; Hui Min Yang; Nicholas Van Halm-Lutterodt; Li Gu; Hong Zhang
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.